Full Name | Joy Tsai |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 300 Pasteur Dr, Stanford, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275913055 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Joy Tsai, 300 Pasteur Drive, Lane 154, Stanford, CA 94305-5133 Ph: (650) 723-6661 | Joy Tsai, 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-6661 |
News Archive
Allergy shots (subcutaneous immunotherapy or SCIT) have been available for more than 100 years. Allergy tablets (sublingual immunotherapy or SLIT) have been approved by the Food and Drug Administration for use in the United States for four years.
At last, the pendulum has swung back to accepting breastfeeding as the norm in infant feeding. Interestingly, this has come about not because of recognition of its natural role in infant care, but because of the revelation of how much it costs the earth to produce "unnecessary formula" for babies and young children, according to a new study published in the British Medical Journal.
A new study by the Substance Abuse and Mental Health Services Administration reveals that daily underage drinking-related visits to hospital emergency departments are 11 percent higher during the Memorial Day weekend than they are on an average day. The latest Drug Abuse Warning Network report estimates that on an average day, there are 519 hospital emergency department visits involving underage alcohol use.
Life Technologies has completed a multi-year license and supply agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently develop new tests for numerous areas of their business.
› Verified 2 days ago